Plus Therapeutics (NASDAQ:PSTV) Earns “Buy” Rating from D. Boral Capital

Plus Therapeutics (NASDAQ:PSTV)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a research report issued on Friday,Benzinga reports. They presently have a $9.00 price target on the stock.

Several other equities research analysts have also recently issued reports on PSTV. Ascendiant Capital Markets reduced their target price on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th. HC Wainwright reduced their price objective on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating on the stock in a research note on Friday.

Plus Therapeutics Stock Down 23.7 %

NASDAQ PSTV opened at $1.16 on Friday. The stock’s 50-day moving average price is $1.11 and its 200-day moving average price is $1.24. The company has a market capitalization of $6.84 million, a P/E ratio of -0.46 and a beta of 0.73. Plus Therapeutics has a 52 week low of $0.24 and a 52 week high of $2.67.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The business had revenue of $1.80 million during the quarter, compared to analyst estimates of $1.19 million. Research analysts anticipate that Plus Therapeutics will post -2.3 EPS for the current year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.